GlassScriptPhysician profile
Yazan Migdady
NPI 1306157458
$13,087.35
in general payments reported to CMS, 2019-2025
14 companies · $5,425 in 2025
The $5,425 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.96 · 2024: $7,617 · 2025: $5,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,688 · Honoraria: $2,048 · Travel and Lodging: $1,726 · Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,688.00 |
| Honoraria | $2,047.50 |
| Travel and Lodging | $1,726.04 |
| Food and Beverage | $579.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $5,237.19 | 2025 | Revuforj |
| Rigel Pharmaceuticals, INC. | $2,905.95 | 2024 | Tavalisse, Rezlidhia |
| Medexus Pharma, INC. | $2,040.00 | 2024 | |
| Servier Pharmaceuticals LLC | $1,960.00 | 2024 | |
| Recordati_rare_diseases_inc. | $688.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $45.96 | 2020 | |
| Incyte Corporation | $44.53 | 2024-2025 | Jakafi |
| Geron Corporation | $38.19 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $25.40 | 2025 | Vanflyta |
| Genentech USA, INC. | $23.08 | 2025 | Venclexta |
| Celgene Corporation | $22.24 | 2025 | Reblozyl |
| Karyopharm Therapeutics INC. | $22.16 | 2025 | Xpovio |
| Sobi, INC | $20.53 | 2025 | |
| Abbvie INC. | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazan Migdady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.